Supriya Lifescience Ltd

Supriya Lifescience Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 March 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

Supriya Lifescience Ltd’s stock declined sharply today, hitting a new 52-week low of Rs.573.45. This drop comes amid broader market weakness and follows two days of gains, marking a notable reversal in the stock’s recent trend.

Supriya Lifescience Ltd witnessed a significant intraday decline on 9 Mar 2026, touching a new 52-week low of Rs 579.9 as the stock faced pronounced selling pressure, underperforming its sector and broader market indices amid a generally weak market environment.

Supriya Lifescience Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 27 February 2026. This shift reflects a combination of deteriorating technical indicators, expensive valuation metrics, flat recent financial performance, and subdued long-term growth prospects. The company’s Mojo Score now stands at 38.0, with a Mojo Grade of Sell, signalling caution for investors amid a challenging market environment.

Supriya Lifescience Ltd has experienced a notable shift in its technical momentum, transitioning from a sideways trend to a bearish stance. This change is underscored by a series of technical indicators signalling increased selling pressure, with the stock currently trading at ₹653.00, down 1.51% from its previous close of ₹663.00. Investors are advised to carefully analyse these developments amid a broader market context where the Sensex has outperformed the stock over recent periods.

Supriya Lifescience Ltd has recently experienced a significant technical development as its 50-day moving average (DMA) crossed below the 200-day moving average, forming a Death Cross. This event is widely regarded by market analysts as a bearish signal, indicating a potential deterioration in the stock’s trend and raising concerns about its medium to long-term price prospects.

Supriya Lifescience Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 20 October 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Supriya Lifescience Ltd has experienced a notable shift in its technical momentum, transitioning from a mildly bullish stance to a sideways trend as of late February 2026. Despite a recent downgrade in its technical grade from Sell to Hold, the stock’s mixed signals across key indicators such as MACD, RSI, and moving averages suggest a complex outlook for investors navigating the Pharmaceuticals & Biotechnology sector.

Supriya Lifescience Ltd has recently exhibited a shift in price momentum, moving from a sideways trend to a mildly bullish stance, supported by a complex interplay of technical indicators. While some metrics signal optimism, others suggest caution, reflecting a nuanced outlook for investors in the Pharmaceuticals & Biotechnology sector.

Supriya Lifescience Ltd has experienced a notable shift in its technical momentum, transitioning from a mildly bullish trend to a sideways pattern. This change is underscored by a complex interplay of technical indicators, including MACD, RSI, Bollinger Bands, and moving averages, which collectively paint a nuanced picture of the stock’s near-term prospects within the Pharmaceuticals & Biotechnology sector.

Supriya Lifescience Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 20 October 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 February 2026, providing investors with the latest insights into its performance and outlook.

Supriya Lifescience Ltd has recently shifted from a sideways technical trend to a mildly bullish stance, supported by a 3.28% gain in the latest trading session. Despite mixed signals from key technical indicators such as MACD, RSI, and moving averages, the stock’s performance relative to the Sensex and its evolving momentum suggest cautious optimism for investors in the Pharmaceuticals & Biotechnology sector.

Supriya Lifescience Ltd has recently exhibited a shift in its technical momentum, moving from a sideways trend to a mildly bullish stance on daily moving averages, despite mixed signals from other key indicators. The stock’s current price of ₹685.80, up 2.52% from the previous close of ₹668.95, reflects cautious optimism among investors amid a challenging broader market environment.

Supriya Lifescience Ltd., a small-cap pharmaceutical company with a market capitalisation of ₹5,517 crores, reported a modest performance in Q3 FY26 (October-December 2025), posting a net profit of ₹49.68 crores, down 1.49% sequentially but up 6.20% year-on-year. The company's stock has declined 0.72% following the results announcement, trading at ₹680.00 as of February 13, 2026, reflecting investor concerns about margin compression and premium valuation despite steady revenue growth.

Supriya Lifescience Ltd has experienced a notable shift in its technical momentum, transitioning from a mildly bullish stance to a sideways trend as of early February 2026. This change is underscored by a complex interplay of technical indicators, including MACD, RSI, moving averages, and Bollinger Bands, reflecting a nuanced outlook for investors in the Pharmaceuticals & Biotechnology sector.